Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D Molecular Therapeutics : Goldman Sachs Starts 4D Molecular Therapeutics at Neutral With $44 Price Target

01/05/2021 | 07:07am EDT


ę MT Newswires 2021
All news about 4D MOLECULAR THERAPEUTICS, INC.
10/264D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
GL
10/264D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
GL
10/264D MOLECULAR THERAPEUTICS INC. : Other Events (form 8-K)
AQ
10/254D MOLECULAR THERAPEUTICS : 4D-310 & 4D-110 Clinical Data Conference Call Presentation
PU
10/254D MOLECULAR THERAPEUTICS : Reports Interim Results from the 4D-310 Phase 1/2 Clinical Tri..
AQ
10/254D Molecular Therapeutics, Inc. Reports Interim Results from the 4D-310 Phase 1/2 Clini..
CI
10/25INSIDER SELL : 4d Molecular Therapeutics
MT
10/134D MOLECULAR THERAPEUTICS INC. : Other Events (form 8-K)
AQ
10/114D MOLECULAR THERAPEUTICS' : 4D-125 Drug Shows Potential in Eye Disease Trial
MT
10/104D MOLECULAR THERAPEUTICS : ASRS 2021 Annual Meeting – 4D-125 for XLRP Phase 1/2 Cli..
PU
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 16,9 M - -
Net income 2021 -71,0 M - -
Net cash 2021 196 M - -
P/E ratio 2021 -12,7x
Yield 2021 -
Capitalization 884 M 884 M -
EV / Sales 2021 40,6x
EV / Sales 2022 259x
Nbr of Employees 104
Free-Float 77,1%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | FDMT | US35104E1001 | MarketScreener
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 32,75 $
Average target price 50,00 $
Spread / Average Target 52,7%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Operating & Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-20.53%884
MODERNA, INC.230.95%141 099
LONZA GROUP AG31.93%60 646
IQVIA HOLDINGS INC.42.93%49 145
SEAGEN INC.1.46%31 933
CELLTRION, INC.-38.02%25 328